With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15529-49-4,Dichlorotris(triphenylphosphino)ruthenium (II),as a common compound, the synthetic route is as follows.
Example B2: Preparation of [(CI)2Ru(Pphenyl3)(ligand L2)], K2tolueneyl 272.5 mg (0.284 mmol) of dichlorotris(triphenylphosphine)ruthenium(ll) and 160.0 mg (0.296 mmol) of ligand L2 are placed in a 10 ml Schlenk tube and admixed with 6.5 ml of dry toluene under argon. The dark suspension is stirred overnight at room temperature, resulting in a colour change to orange-red. After addition of 4 ml of dry pentane, the stirrer is switched off and the supernatant orange solution is filtered off with suction from the orange solid. The solid is washed five times with 4 ml each time of pentane and dried in a high vacuum. This gives 244 mg (88% of theory) of the title compound as an orange powder. 31P-NMR (C6D6, 121.5 MHz, ppm): 49.7 (d, J = 40), 61.2 (d, J = 40).
As the paragraph descriping shows that 15529-49-4 is playing an increasingly important role.
Reference£º
Patent; SOLVIAS AG; WO2007/104690; (2007); A1;,
Highly efficient and robust molecular ruthenium catalysts for water oxidation
Catalysts | Special Issue : Ruthenium Catalysts – MDPI